argenx
(NASDAQ: ARGX)
|
5:00 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $435.29 | Change: -0.20 | %Change: -0.05% | Volume: 197,750 |
Open: | $ 437.04 | Volume: | 197,750 | |
---|---|---|---|---|
High: | $ 438.55 | Yield(%) | 0.00 | |
Low: | $ 433.35 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 25.88B | |
EPS ($) | -1.06 | Shares Out: | 59.43M |
% Price Change (last 4 weeks): | 15.03 |
---|---|
% Price Change (last 13 weeks): | 9.66 |
% Price Change (last 26 weeks): | 14.30 |
% Price Change (last 52 weeks): | 14.13 |
% Price Change (year to date): | 14.47 |
Return on Equity (%): | -8.55 |
---|---|
Return on Assets (%): | -7.70 |
Return on Invested Capital (%): | -23.35 |
Gross Profit Margin (%): | 81.59 |
---|---|
Net Profit Margin (%): | -24.06 |
Operating Profit Margin (%): | -36.78 |
|
|
50-day Moving Average: | $385.47 |
---|---|
200-day Moving Average: | $417.59 |
Avg. Daily Vol. (last 50 days): | 303,047 |
Avg. Daily Vol. (last 200 days): | 338,654 |
52-wk high: | $550.76 |
52-wk low: | $327.73 |
Bid: | $423.91 |
Ask: | $445.06 |
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
|
argenx
Laarderhoogtweg 25 Amsterdam NH 1101 EB Phone: 31.76.303.04.88 Fax: n/a http://www.argen-x.com |
Earnings (1year) ($): | -5.17 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 69.22 |
Cash Flow ($): | -3.11 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 17.71 |
Price/Book (x): | 5.50 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 9.01 |
---|---|
Current Ratio (x): | 9.75 |
LT Debt/Equity (x): | 0.37 |
Total Debt/Equity (x): | 0.49 |